Post-appeal final appraisal determination: Psoriasis - efalizumab and etanercept
The post-appeal FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales.
Please note that the appeal period for this appraisal will close at 5pm Friday 23rd June 2006.
Post-appeal final appraisal determination: Psoriasis - efalizumab and etanercept
09 June 2006 (174.89 Kb 50 sec) |
This page was last updated: 30 March 2010